紫杉类药物新辅助治疗老年卵巢癌患者的疗效及安全性分析

Efficacy and safety analysis of yew neoadjuvant therapy in elderly patients with ovarian cancer

目的分析紫杉类药物新辅助治疗老年卵巢癌(OC)的临床效果及安全性。方法选取72例行新辅助治疗的老年OC患者,采用随机抽签法分为对照组(采用紫杉醇注射液治疗)与研究组(采用紫杉醇脂质体药物治疗),每组36例。比较两组临床疗效、不良反应发生情况及疗效满意度评分。结果治疗后研究组患者总缓解率为91.67%,明显高于对照组的72.22%,差异有统计学意义(P<0.05)。两组Ⅰ~Ⅱ期患者不良反应发生率比较,差异无统计学意义(P>0.05);研究组Ⅲ~Ⅳ期患者不良反应发生率低于对照组,差异具有统计学意义(P<0.05)。研究组疗效满意度评分(90.38±2.83)分高于对照组的(84.38±3.92)分,差异具有统计学意义(P<0.05)。结论紫杉类脂质体药物新辅助疗法在老年OC患者中疗效确切,在Ⅲ~Ⅳ期患者中不良反应风险略低。

Objective To analyze the clinical effect and safety of yew neoadjuvant therapy in the treatment of senile ovarian cancer(OC).Methods 72 elderly OC patients receiving neoadjuvant therapy were selected and divided into control group(treated with paclitaxel injection)and study group(treated with paclitaxel liposome)by random drawing method,with 36 cases in each group.The clinical efficacy,occurrence of adverse reactions and efficacy satisfaction score were compared between the two groups.Results After treatment,the total remission rate of the study group was 91.67%,which was significantly higher than that of the control group 72.22%,and the difference was statistically significant(P<0.05).There was no significantⅠ~Ⅱin the incidence of adverse reactions between the two groups(P>0.05).The incidence of adverse reactions inⅢ~Ⅳpatients in the study group was lower than that in the control group,and the difference was statistically significant(P<0.05).The satisfaction score of the study group(90.38±2.83)points was higher than that of the control group(84.38±3.92)points,and the difference was statistically significant(P<0.05).Conclusion Neoadjuvant therapy with taxoid liposomes is effective in elderly patients with OC,and the risk of adverse reactions is slightly lower in patients with stageⅢ~Ⅳ.